The Eaton Vance Management holds 58,270 shares with $26.05 million value, up from 56,770 last quarter. Gilead Sciences Inc now has $95.42 billion valuation. The stock decreased 2.49% or $2.99 during the last trading session, reaching $117. REGN's total short interest was 1.94 million shares in March as published by FINRA. It has underperformed by 16.70% the S&P500.
Nippon Life Insurance Company increased Regeneron Pharmaceuticals (REGN) stake by 29.66% reported in 2017Q3 SEC filing. The Diversified Trust Co holds 3,605 shares with $1.61 million value, down from 5,200 last quarter.
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by ValuEngine from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Thursday, March 1st. 127 funds opened positions while 474 raised stakes. (NASDAQ:REGN) for 99 shares. 900 were accumulated by John G Ullman And Assoc. Caxton L P holds 0.01% or 600 shares. Next Century Growth Investors Limited Com reported 0.09% in Regeneron Pharmaceuticals, Inc. (NASDAQ:GILD). Hodges Capital Mgmt Inc holds 40,639 shares. Cypress Asset Mngmt Tx holds 0.83% in Regeneron Pharmaceuticals, Inc. (NASDAQ:GILD) for 1.08M shares. New York-based Duquesne Family Office Ltd has invested 0.65% in Regeneron Pharmaceuticals, Inc. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company's stock worth $286,619,000 after purchasing an additional 3,131,966 shares in the last quarter. Capital Counsel Llc Ny owns 614,470 shares or 6.1% of their United States portfolio. Homrich And Berg has 7,577 shares. Cambridge Investment Research Advisors Inc. increased its holdings in Regeneron Pharmaceuticals by 2.8% during the fourth quarter. (NASDAQ:GILD) for 7,826 shares.
Analysts await Visa Inc. (NYSE:RHT) to report earnings on March, 26 after the close. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $1.05. $4.18 million worth of Gilead Sciences, Inc. (NASDAQ:REGN) was sold by BROWN MICHAEL S. The shares were sold at an average price of $350.02, for a total transaction of $700,040.00. Another trade for 6,220 shares valued at $707,561 was sold by MATSCHULLAT ROBERT W. $401,566 worth of Gilead Sciences, Inc. (NASDAQ:REGN) for 41,944 shares. (NASDAQ:GILD) shares. WILSON GAYLE E sold $4.68M worth of stock. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since March 25, 2017 and is uptrending. Therefore 81% are positive. Bank Of Montreal had 61 analyst reports since August 20, 2015 according to SRatingsIntel. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) rating on Tuesday, July 11. As per Thursday, November 9, the company rating was maintained by SunTrust. Argus reduced their price target on Regeneron Pharmaceuticals from $540.00 to $470.00 and set a "buy" rating on the stock in a research note on Thursday, December 28th. As per Friday, February 2, the company rating was maintained by Morgan Stanley. The firm earned "Buy" rating on Friday, May 5 by Canaccord Genuity. Jefferies maintained the stock with "Hold" rating in Wednesday, October 4 report. The firm has "Buy" rating by Piper Jaffray given on Thursday, September 7. Fjarde Ap accumulated 18,377 shares. (NYSE:V) or 1,712 shares. Ppg Inds Inc (NYSE:PPG) was reduced too. First Tru Advsr Limited Partnership invested 0.17% in Regeneron Pharmaceuticals, Inc.
Several research firms have recently issued reports on REGN. During the same period a year ago, the company earned $3.04 EPS. RHT's profit will be $104.43 million for 62.67 P/E if the $0.59 EPS becomes a reality. The stock of Regeneron Pharmaceuticals, Inc.
Since September 29, 2017, it had 0 buys, and 5 insider sales for $3.32 million activity. GOLDSTEIN JOSEPH L sold $325,600 worth of Regeneron Pharmaceuticals, Inc. During the same quarter in the previous year, the firm posted $3.04 earnings per share. equities analysts expect that Regeneron Pharmaceuticals will post 19.2 earnings per share for the current year. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Therefore 39% are positive. Allsquare Wealth Management Ltd Co stated it has 0.03% in Regeneron Pharmaceuticals, Inc. Vident Investment Advisory LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth about $200,000. (NASDAQ:REGN). Tower Rech Capital Ltd Llc (Trc) stated it has 477 shares. Oppenheimer maintained the shares of V in report on Friday, June 23 with "Buy" rating. Advisory Services Network LLC lifted its stake in Regeneron Pharmaceuticals by 147.0% in the fourth quarter. Zacks has "Hold" rating and $668 target. The stock has a market capitalization of $34,601.65, a P/E ratio of 23.25, a P/E/G ratio of 1.01 and a beta of 1.54. The company was downgraded on Friday, December 1 by Citigroup.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
Black Caps four wickets from Test triumph
The innings was only into its third over when Trent Boult had Alastair Cook caught down the leg side by Watling for two. England's Joe Root reacts after being bowled during the first day of the first cricket test match.
Prince Harry and Meghan Markle on NI visit
Middleton's McQueen gown, which was custom-designed by creative director Sarah Burton, included the same features. She said: " Prince Harry , particularly, is very keen to start a family , pretty soon after the royal wedding".
" "Timo Werner - "€100m target for Jurgen Klopp"
However, while on worldwide duty, Werner quickly responded to talk that he was looking for a move away from Leipzig. However, Werner gave an exclusive interview to Kicker on Sunday evening whilst on worldwide duty with Germany.